Your session is about to expire
← Back to Search
177Lu-PSMA-617 + Standard Therapy for Prostate Cancer (PSMAddition Trial)
PSMAddition Trial Summary
This trial is testing a new cancer treatment in men with mHSPC. The new treatment is given with the standard of care, which is a combination of two existing treatments. 1126 patients will be randomly assigned to either the new treatment or the standard of care.
PSMAddition Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPSMAddition Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 831 Patients • NCT03511664PSMAddition Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had specific radiation treatments or PSMA-targeted therapy in the last 6 months.I agree to use a condom during the study and for 14 weeks after, and not to donate sperm.I am not currently on any strong cancer treatments like chemotherapy.You have taken any experimental drugs within the last 30 days before the start of the study.I do not have any mental or physical health conditions that could affect the study's results.I cannot raise my arms.My liver function tests are within the required limits.I have been cancer-free for over 3 years, except for non-melanoma skin cancer or superficial bladder cancer.I am 18 years old or older.I can take care of myself and am up and about more than half of my waking hours.I have prostate cancer that has spread, confirmed by a biopsy.I have prostate cancer and have had minimal or no prior treatment.I have cancer that has spread to my bones, lymph nodes, or other organs.I have metastatic prostate cancer and am expected to live more than 9 months.My cancer is growing quickly and needs immediate treatment with taxane-based chemotherapy.I have not received a transfusion just to qualify for this study.My bladder issues are under control with current treatments.I have serious heart issues or a family history of severe heart problems.My cancer has spread to my bones, lymph nodes outside the pelvis, or other organs.I am experiencing symptoms or have been diagnosed with potential spinal cord compression.I have not had any prostate cancer treatment except for those listed in criteria 11.My brain metastases are stable, and I'm not on steroids for them.
- Group 1: 177Lu-PSMA-617
- Group 2: Standard of Care
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any current openings for enrollees in this experiment?
"That is accurate, the ongoing clinical trial is recruiting 1126 participants from 52 sites, as stated on clinicaltrials.gov. The first posting was on June 9th, 2021 and the most recent edit was on October 26th, 2022."
Do most of the trial locations for this research project fall within North America?
"Currently, there are 52 locations across the country enrolling patients for this study. If you're interested in participating, it may be helpful to select a location near you to minimize travel-related logistics."
Is there a high risk of danger for people using 177Lu-PSMA-617?
"According to our team's assessment, 177Lu-PSMA-617 rates a 3 on the safety scale. This is due to it being in Phase 3 trials, which means that there is both efficacy data as well as multiple rounds of safety data supporting its use."
What is the maximum number of participants in this experiment?
"The sponsor, Novartis Pharmaceuticals, needs to recruit 1126 patients that match the study's inclusion criteria from different sites including University of Pittsburgh Cancer Institute SC-3 in Pittsburgh, Pennsylvania and UT Health San Antonio Mays Cancer Center in San Antonio, Texas."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- Novartis Investigative Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger